DOCSLIB.ORG

Dermatology Pearls for the Primary Care Practitioner‐ Part 2 Outline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dermatology Pearls for the Primary Care Practitioner‐ Part 2 Outline Dermatology Pearls for the Outline Primary Care Practitioner‐ Part 2 • Chronic urticaria • Onychomycosis Lindy P. Fox, MD • The red leg Professor of Clinical Dermatology Director, Hospital Consultation Service • Grovers disease Department of Dermatology • University of California, San Francisco Pearls to know [email protected] I have no conflicts of interest to disclose I may be discussing off-label use of medications 1 2 • 36 yoF complains of 2 mo of urticaria • Lesions last < 24 hours, itchy • Failed loratadine 10 mg daily Chronic Urticaria 3 Chronic Urticaria Chronic Urticaria‐ Workup • History and physical guides workup • Urticaria, with or without angioedema > 6 • Labs to check weeks – CBC with differential – Lesions last < 24 hours, itch, completely resolve – ESR, CRP • Divided into chronic spontaneous (66‐93%) – TSH and thyroid autoantibodies or chronic inducible – Liver function tests • Natural history‐ 2‐5 years – CU Index (Fc‐εRIα Ab or Ab to IgE) – > 5 yrs in 20% patients – Maybe tryptase for severe, chronic recalcitrant disease – 13% relapse rate – Maybe look for bullous pemphigoid in an older patient • Etiology • Provocation for inducible urticaria – 30 ‐50 % ‐ IgG autoAb to IgE or FcεRIα Eur J Dermatol 2016 – Remainder, unclear Clin Transl Allergy 2017. 7(1): 1‐10 Eur J Dermatol 2016 Allergy Asthma Immunol Res. 2016;8(5):396‐403 J Allergey Clin Immunol Pract. 2017. Sept 6. S2213‐2198 Clin Transl Allergy 2017. 7(1): 1‐10 First line Chronic Spontaneous Urticaria‐ Treatment nd H1 antihistamines‐ 2 generation <40% respond to standard dose H1 blockade Avoid triggers (NSAIDS, ASA) Can increase to up to 4X standard dose What does my “second line” look like? 60% chance of response Second line • Fexofenadine 360 mg am, 180 mg noon, 360 mg pm nd High dose 2 generation AH • Cetirizine 10 mg BID Add another 2nd generation AH 1st gen H1 antihistamine QHS • Hydroxyzine 25 mg QHS +/‐ H2 antagonist • +/‐ Monteleukast 10 mg QD +/‐ Leukotriene antagonist Third line • +/‐ Ranitidine 300 mg QD Omalizumab Cyclosporine • Give epipens (3) Dapsone Sulfasalazine J Allergy Clin Immunol 2014. 133(3):914‐5 Hydroxychloroquine BJD 2016. 175:1134–52 Mycophenolate mofetil Clin Transl Allergy 2017. 7(1): 1‐10 • When time to taper, take off 1 pill per week Allergy Asthma Immunol Res. 2016;8(5):396‐403 TNFα antagonists Eur J Dermatol 2016 (epub ahead of print) Anti CD20 Ab (rituximab) Allergy Asthma Immunol Res. 2017 November;9(6):477‐482. Allergy 2018. Jan 15. epub ahead of print CSU‐ when to refer • Atypical lesion morphology or symptoms – > 24 hours, central duskiness/purpura – Asymptomatic or burn >> itch Onychomycosis • Minimal response to medications – High dose H1 nonsedating antihistamines – H1 sedating antihistamines • Associated symptoms – Fever, fatigue, mylagias, arthralgias • Elevated ESR/CRP 10 Onychomycosis Onychomycosis • Infection of the nail plate by fungus • Vast majority are due to dermatophytes, especially Trichophyton rubrum • Very common • Increases with age • Half of nail dystrophies are onychomycosis • This means 50% of nail dystrophies are NOT fungal 11 12 Onychomycosis Onychomycosis Diagnosis • KOH is the best test, as it is cheap, accurate if positive, and rapid; Positive 59% • If KOH is negative, perform a fungal culture • Frequent contaminant overgrowth • 53% positive • Nail clipping • Send to pathology lab to be sectioned and stained with special stains for fungus • Accurate (54% positive), rapid (<7d), written report • Downside: Cost (>$100) 13 14 Onychomycosis Onychomycosis: Local Treatment Interpreting Nail Cultures • Laser‐ insufficient data that it works • Any growth of T. rubrum is significant • Topical Therapy: • Contaminants • Ciclopirox (Penlac) 8% Lacquer: – Not considered relevant unless grown twice • Cure rates 30% to 35% for mild to moderate onychomycosis from independent samples AND no (20% to 65% involvement) dermatophyte is cultured • Clinical response about 65% – Relevant contaminants: • Efinaconazole (Jublia) 10%* • C. albicans • Daily for 48 weeks • Scopulariopsis brevicaulis • Complete or almost complete cure (completely clear nail)‐ 26% • Fusarium • Mycologic cure (neg KOH and neg fungal cx)‐ 55% • Scytalidium (Carribean, Japan, Europe) • Tavaborole (Kerydin) 5%* – Especially in immunosuppressed patients • Daily for 48 weeks • Complete or almost complete cure (completely clear nail)‐ 15‐17% • Mycologic cure (neg KOH and neg fungal cx)‐ 31‐36% 15 16 *Data from pharma website Onychomycosis Onychomycosis: Systemic Treatment Assessing Treatment Efficacy • Itraconazole: • Nail growth – 200 mg/d for 3 months – At 2 to 3 months nail begins to grow out – 400 mg/d for one week per month for 4 months – Continues for 12 months • Terbinafine: 250mg po QD • Repeat KOH/culture at 4-6 months – Fingernails: 6 weeks – If culture still positive, treatment will likely fail – Toenails: 12 weeks – KOH may still be positive (dead dermatophytes) • Check LFTs at 6 weeks • Failures – Pulse dosing – Terbinafine resistance • 500 mg daily for one week monthly for 3 months – Non-dermatophyte molds – Efficacy: 35% complete cures; 60% clinical cures – Dermatophytoma 17 18 The red leg: Cellulitis and its (common) mimics • Cellulitis/erysipelas • Stasis dermatitis • Contact dermatitis 19 Cellulitis • Infection of the dermis • Gp A beta hemolytic strep and Staph aureus • Rapidly spreading • Erythematous, tender plaque, not fluctuant • Patient often toxic • WBC, LAD, streaking • Rarely bilateral • Treat tinea pedis Stasis Dermatitis Contact Dermatitis • Often bilateral, L>R • Itch (no pain) • Itchy and/or painful • Patient is non‐toxic • Red, hot, swollen leg • Erythema and • No fever, elevated WBC, edema can be severe LAD, streaking • Look for: varicosities, • Look for sharp cutoff edema, venous ulceration, • Treat with topical hemosiderin deposition steroids • Superimposed contact dermatitis common Contact Dermatitis • Common causes – Applied antibiotics (Neomycin, Bacitracin) – Topical anesthetics (benzocaine) Grover’s Disease – Other (Vitamin E, topical diphenhydramine) • Avoid topical antibiotics to leg ulcers – Metronidazole OK (prevents odor) 28 Grovers Disease (transient acantholytic dermatosis) • Sudden eruption of papules, papulovesicles; often crusted • Mid chest and back • Itchy • Middle aged to older men • Etiology unknown‐ heat, sweating • Risk factors: hospitalized, febrile, sun damage • Transient • Treatment: topical steroids (triamcinolone 0.1% cream); get patient to move around Pearls to know Pustular Psoriasis • Pustular and erythrodermic variants of psoriasis • Can be life‐threatening • Most common in patients who carry a diagnosis of psoriasis who have been given systemic steroids and then tapered • High cardiac output state with risk of high output failure • Electrolyte imbalance (Ca2+), respiratory distress, temperature dysregulation • Best treated with hospitalization and cyclosporine or acitretin 33 34 35 36 Lotrisone Tinea Incognito • Combination of betamethasone plus clotrimazole – Weak antifungal + superpotent steroid • Inadequate to kill fungus and may cause complications (striae, fungal folliculitis) • Dermatologists rarely use it • Rarely indicated 37 38 Case • 67M underwent an elective saphenous vein phlebectomy for asymptomatic varicosities • 4d post op, he develops erythema around the wound. • Ulceration continues to expand despite multiple debridements and broad spectrum antibiotics. • Wound cultures are negative • 3 weeks later, he is transferred to UCSF and a dermatology consultation is called • Tmax 104, WBC 22 Pyoderma Gangrenosum • Rapidly progressive (days) ulcerative process • Begins as a small pustule which breaks down forming an ulcer • Undermined violaceous border • Expands by small peripheral satellite ulcerations which merge with the central larger ulcer • Occur anywhere on body • Triggered by trauma (pathergy) (surgical debridement, attempts to graft) Pyoderma Gangrenosum Pyoderma Gangrenosum • 50% have no • Workup underlying cause – Skin biopsy for H&E and culture • Associations (50%): – Rheumatoid factor – Inflammatory bowel disease (1.5%-5% of – SPEP/UPEP IBD patients get PG) – ANCA (ulcers of Granulomatosis with – Rheumatoid arthritis Polynagiitis can mimic PG) – Seronegative arthritis – Colonscopy (r/o IBD) – Hematologic – Peripheral smear, Bone marrow biopsy (r/o abnormalities (AML) AML) Pyoderma Gangrenosum Treatment • AVOID DEBRIDEMENT • Refer to dermatology • Treatment of underlying disease may not help PG – Topical therapy: • Superpotent steroids • Topical tacrolimus – Systemic therapy: • Systemic steroids • Cyclosporine or Tacrolimus • Cellcept • Thalidomide • TNF-blockers (Remicade) A few simple rules to live by: • Nummular dermatitis- requires 18 mo treatment • Alopecia- nonscarring (eval, treat) vs scarring (refer) • Spironolactone for acne in adult women • Limit duration of oral antibiotics for acne to < 6mo • Almost all acne patients benefit from topical retinoids • Chronic urticaria- antihistamines at 4x standard dose • Onychomycosis treatment efficacy: oral > topical • Cellulitis is almost never bilateral • Treat tinea pedis in patients with cellulitis • Never use lotrisone.
Load more

Recommended publications
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Malassezia Furfur Folliculitis in Cancer Patients. the Need for Interaction Of
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 23, No. 5 Copyright © 1993, Institute for Clinical Science, Inc. Malassezia furfur Folliculitis in Cancer Patients The Need for Interaction of Microbiologist, Surgical Pathologist, and Clinician in Facilitating Identification by the Clinical Microbiology Laboratory* RAMON L. SANDIN, M.D., M.S.,f TZANN-TARN FANG, M.D.,* JOHN W. HIEMENZ, M.D.,t JOHN N. GREENE, M.D.,§ LINA CARD, M.T. (ASCP),t ALEXANDRA KALIK, M.D.,t and JENO E. SZAKACS, M.D.t Departments of Pathology, f Bone Marrow Transplant Service,t and Infectious Diseases,§ H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612-9497 ABSTRACT Malassezia furfur (MF) is a lipophilic yeast which can be found as a member of the indigenous microbiota of human skin. In immunocompro­ mised transplant patients, MF can cause a distinctive folliculitis which is a clinical look-alike to Candida folliculitis, the latter of more potentially devastating significance. Recovery of MF in culture is dependent upon the addition to culture media of an exogenous source of fatty acids, such as olive oil. The addition of an extra Sabourauds plate with an olive oil overlay to the routine set of media used to inoculate all skin biopsy specimens in order to detect MF is labor-intensive and not cost-effective. Thus, MF may not be isolated in cases of MF folliculitis unless the clinical microbiology laboratory is put on alert by the clinical suspicions of the attending physi­ cian, or by histopathologic findings suggestive of folliculitis revealed by review of surgical pathology slides.
    [Show full text]
  • WO 2009/132342 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 29 October 2009 (29.10.2009) WO 2009/132342 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/107 (2006.01) A61P 31/10 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (21) International Application Number: EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2009/04181 1 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 27 April 2009 (27.04.2009) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, (25) Filing Language: English SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, (26) Publication Language: English UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/048,075 25 April 2008 (25.04.2008) US kind of regional protection available): ARIPO (BW, GH, 61/129,962 1 August 2008 (01 .08.2008) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 61/1 15,879 18 November 2008 (18.1 1.2008) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, (71) Applicant (for all designated States except US): ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, NANOBIO CORPORATION [US/US]; 23 11 Green MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), Road, Suite A, Ann Arbor, MI 48105 (US).
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • | Oa Tai Ei Rama Telut Literatur
    |OA TAI EI US009750245B2RAMA TELUT LITERATUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,750 ,245 B2 Lemire et al. ( 45 ) Date of Patent : Sep . 5 , 2017 ( 54 ) TOPICAL USE OF AN ANTIMICROBIAL 2003 /0225003 A1 * 12 / 2003 Ninkov . .. .. 514 / 23 FORMULATION 2009 /0258098 A 10 /2009 Rolling et al. 2009 /0269394 Al 10 /2009 Baker, Jr . et al . 2010 / 0034907 A1 * 2 / 2010 Daigle et al. 424 / 736 (71 ) Applicant : Laboratoire M2, Sherbrooke (CA ) 2010 /0137451 A1 * 6 / 2010 DeMarco et al. .. .. .. 514 / 705 2010 /0272818 Al 10 /2010 Franklin et al . (72 ) Inventors : Gaetan Lemire , Sherbrooke (CA ) ; 2011 / 0206790 AL 8 / 2011 Weiss Ulysse Desranleau Dandurand , 2011 /0223114 AL 9 / 2011 Chakrabortty et al . Sherbrooke (CA ) ; Sylvain Quessy , 2013 /0034618 A1 * 2 / 2013 Swenholt . .. .. 424 /665 Ste - Anne -de - Sorel (CA ) ; Ann Letellier , Massueville (CA ) FOREIGN PATENT DOCUMENTS ( 73 ) Assignee : LABORATOIRE M2, Sherbrooke, AU 2009235913 10 /2009 CA 2567333 12 / 2005 Quebec (CA ) EP 1178736 * 2 / 2004 A23K 1 / 16 WO WO0069277 11 /2000 ( * ) Notice : Subject to any disclaimer, the term of this WO WO 2009132343 10 / 2009 patent is extended or adjusted under 35 WO WO 2010010320 1 / 2010 U . S . C . 154 ( b ) by 37 days . (21 ) Appl. No. : 13 /790 ,911 OTHER PUBLICATIONS Definition of “ Subject ,” Oxford Dictionary - American English , (22 ) Filed : Mar. 8 , 2013 Accessed Dec . 6 , 2013 , pp . 1 - 2 . * Inouye et al , “ Combined Effect of Heat , Essential Oils and Salt on (65 ) Prior Publication Data the Fungicidal Activity against Trichophyton mentagrophytes in US 2014 /0256826 A1 Sep . 11, 2014 Foot Bath ,” Jpn .
    [Show full text]
  • Therapies for Common Cutaneous Fungal Infections
    MedicineToday 2014; 15(6): 35-47 PEER REVIEWED FEATURE 2 CPD POINTS Therapies for common cutaneous fungal infections KENG-EE THAI MB BS(Hons), BMedSci(Hons), FACD Key points A practical approach to the diagnosis and treatment of common fungal • Fungal infection should infections of the skin and hair is provided. Topical antifungal therapies always be in the differential are effective and usually used as first-line therapy, with oral antifungals diagnosis of any scaly rash. being saved for recalcitrant infections. Treatment should be for several • Topical antifungal agents are typically adequate treatment weeks at least. for simple tinea. • Oral antifungal therapy may inea and yeast infections are among the dermatophytoses (tinea) and yeast infections be required for extensive most common diagnoses found in general and their differential diagnoses and treatments disease, fungal folliculitis and practice and dermatology. Although are then discussed (Table). tinea involving the face, hair- antifungal therapies are effective in these bearing areas, palms and T infections, an accurate diagnosis is required to ANTIFUNGAL THERAPIES soles. avoid misuse of these or other topical agents. Topical antifungal preparations are the most • Tinea should be suspected if Furthermore, subsequent active prevention is commonly prescribed agents for dermatomy- there is unilateral hand just as important as the initial treatment of the coses, with systemic agents being used for dermatitis and rash on both fungal infection. complex, widespread tinea or when topical agents feet – ‘one hand and two feet’ This article provides a practical approach fail for tinea or yeast infections. The pharmacol- involvement. to antifungal therapy for common fungal infec- ogy of the systemic agents is discussed first here.
    [Show full text]
  • Tinea Genitalis: a New Entity of Sexually Transmitted Infection? Case Series and Review of the Literature
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2015 Tinea genitalis: a new entity of sexually transmitted infection? Case series and review of the literature Luchsinger, Isabelle ; Bosshard, Philipp Peter ; Kasper, Romano Silvio ; Reinhardt, Dominic ; Lautenschlager, Stephan Abstract: OBJECTIVE Investigation on recent cases of tinea genitalis after travelling to South East Asia. METHODS Patients with tinea in the genital region, which emerged after sex in South East Asia, underwent further assessment including microscopy, cultures and DNA analyses. RESULTS The case series includes seven patients. In six patients, Trichophyton interdigitale (former Trichophyton mentagrophytes) was detected. Three patients suffered from a severe inflammatory reaction of thesoft tissue and two of them needed hospitalisation due to severe pain. In four patients, cicatrising healing was noticed. Five patients were declared incapacitated for work. CONCLUSIONS Sexual activity should be considered as a potentially important and previously underappreciated means of transmission of T. interdigitale. To avoid irreversible scarring alopecia, prompt initiation of antifungal treatment is essential and adequate isolation and identification of the pathogen is mandatory. DOI: https://doi.org/10.1136/sextrans-2015-052036 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-113887 Journal Article Published Version Originally published at:
    [Show full text]
  • Young Adults Young Adults (20 - 35 Years)
    YOUNG ADULTS YOUNG ADULTS (20 - 35 YEARS) A large number of skin diseases reach their peak of expression during the young adult years, and these individuals also represent a large and growing proportion of the South African population, in common with other developing countries. Young adults are especially distressed by skin conditions that are uncomfortable, disfiguring or contagious. This group has also been severely affected by HIV/AIDS, with a consequent increase in the frequency and severity of the HIV- associated dermatoses. Some of these conditions have been discussed in other sections of this review. ACNE KELOIDALIS Inflammatory papules and pustules located mainly on the nape of the neck and occiput characterise this acne-like condition. It primarily affects black males. The lesions heal with scarring, creating huge keloids if this tendency exists. The cause is unknown, and unlikely to result from repeated shaving or short hair cutting. It DENGA A MAKHADO may be caused by unusually thick collagen, which traps and disrupts terminal MB ChB, FCDerm (SA) hair follicles. Treatment is not very successful, and large keloids are best excised Consultant Dermatologist by a surgeon. Mild cases can be helped by intralesional injection of steroids like Division of Dermatology Celestone Soluspan into individual papules and scars. Long-term oral tetracy- clines, as for acne, can also be beneficial, as can topical antibiotics like erythro- University of the Witwatersrand and mycin and clindamycin. Chris Hani Baragwanath Hospital Johannesburg ACNE VULGARIS Denga Anna Makhado is a consultant der- There has been a recent tendency for acne to persist beyond the teens, or even matologist at Chris Hani Baragwanath occur for the first time in adulthood, called persistent adult acne.
    [Show full text]
  • In Fungi and Their Interactions
    IN FUNGI AND THEIR INTERACTIONS Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform George Tegos, Tianhong Dai, Beth B Fuchs, Jeffrey J Coleman, Renato Araujo Prates, Christos Astrakas, Tyler G St Denis, Martha S Ribeiro, Eleftherios Mylonakis and Michael R Hamblin Journal Name: Frontiers in Microbiology ISSN: 1664-302X Article type: Review Article Received on: 15 Jan 2012 Accepted on: 13 Mar 2012 Provisional PDF published on: 13 Mar 2012 Frontiers website link: www.frontiersin.org Citation: Tegos G, Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C, St denis TG, Ribeiro MS, Mylonakis E and Hamblin MR(2012) Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front. Microbio. 3:120. doi:10.3389/fmicb.2012.00120 Article URL: http://www.frontiersin.org/Journal/Abstract.aspx?s=727& name=fungi%20and%20their%20interactions&ART_DOI=10.3389 /fmicb.2012.00120 (If clicking on the link doesn't work, try copying and pasting it into your browser.) Copyright statement: © 2012 Tegos, Dai, Fuchs, Coleman, Prates, Astrakas, St denis, Ribeiro, Mylonakis and Hamblin. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited. This Provisional PDF corresponds to the article as it appeared upon acceptance, after rigorous peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon. Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform Tianhong Dai,1,2 Beth B.
    [Show full text]
  • Evidence-Based Danish Guidelines for the Treatment of Malassezia- Related Skin Diseases
    Acta Derm Venereol 2015; 95: 12–19 SPECIAL REPORT Evidence-based Danish Guidelines for the Treatment of Malassezia- related Skin Diseases Marianne HALD1, Maiken C. ARENDRUP2, Else L. SVEJGAARD1, Rune LINDSKOV3, Erik K. FOGED4 and Ditte Marie L. SAUNTE5; On behalf of the Danish Society of Dermatology 1Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, 2 Unit for Mycology, Statens Serum Institut, 3The Dermatology Clinic, Copen- hagen, 4The Dermatology Clinic, Holstebro, and 5Department of Dermatology, Roskilde Hospital, University of Copenhagen, Denmark Internationally approved guidelines for the diagnosis including those involving Malassezia (2), guidelines and management of Malassezia-related skin diseases concerning the far more common skin diseases are are lacking. Therefore, a panel of experts consisting of lacking. Therefore, a panel of experts consisting of dermatologists and a microbiologist under the auspi- dermatologists and a microbiologist appointed by the ces of the Danish Society of Dermatology undertook a Danish Society of Dermatology undertook a data review data review and compiled guidelines for the diagnostic and compiled guidelines on the diagnostic procedures procedures and management of pityriasis versicolor, se- and management of Malassezia-related skin diseases. borrhoeic dermatitis and Malassezia folliculitis. Main The ’head and neck dermatitis’, in which hypersensi- recommendations in most cases of pityriasis versicolor tivity to Malassezia is considered to be of pathogenic and seborrhoeic dermatitis include topical treatment importance, is not included in this review as it is restric- which has been shown to be sufficient. As first choice, ted to a small group of patients with atopic dermatitis. treatment should be based on topical antifungal medica- tion.
    [Show full text]
  • Differential Diagnosis of the Scalp Hair Folliculitis
    Acta Clin Croat 2011; 50:395-402 Review DIFFERENTIAL DIAGNOSIS OF THE SCALP HAIR FOLLICULITIS Liborija Lugović-Mihić1, Freja Barišić2, Vedrana Bulat1, Marija Buljan1, Mirna Šitum1, Lada Bradić1 and Josip Mihić3 1University Department of Dermatovenereology, 2University Department of Ophthalmology, Sestre milosrdnice University Hospital Center, Zagreb; 3Department of Neurosurgery, Dr Josip Benčević General Hospital, Slavonski Brod, Croatia SUMMARY – Scalp hair folliculitis is a relatively common condition in dermatological practice and a major diagnostic and therapeutic challenge due to the lack of exact guidelines. Generally, inflammatory diseases of the pilosebaceous follicle of the scalp most often manifest as folliculitis. There are numerous infective agents that may cause folliculitis, including bacteria, viruses and fungi, as well as many noninfective causes. Several noninfectious diseases may present as scalp hair folli- culitis, such as folliculitis decalvans capillitii, perifolliculitis capitis abscendens et suffodiens, erosive pustular dermatitis, lichen planopilaris, eosinophilic pustular folliculitis, etc. The classification of folliculitis is both confusing and controversial. There are many different forms of folliculitis and se- veral classifications. According to the considerable variability of histologic findings, there are three groups of folliculitis: infectious folliculitis, noninfectious folliculitis and perifolliculitis. The diagno- sis of folliculitis occasionally requires histologic confirmation and cannot be based
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0276182 A1 Baker, JR
    US 20120276.182A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0276182 A1 Baker, JR. et al. (43) Pub. Date: Nov. 1, 2012 (54) METHODS OF TREATING FUNGAL, YEAST Publication Classification AND MOLD INFECTIONS (51) Int. C. Inventors: James R. Baker, JR. Ann Arbor, A6II 47/44 (2006.01) (75) A6II 3/53 (2006.01) MI (US); Mary R. Flack, Ann A638/12 (2006.01) Arbor, MI (US); Susan M. Ciotti, A63L/7048 (2006.01) Ann Arbor, MI (US); Joyce A. A 6LX 9/07 (2006.01) Sutcliffe, West Newton, MA (US) A63L/464 (2006.01) (73) Assignee: Nanobio Corporation A 6LX 3/5.375 (2006.01) B82Y5/00 (2011.01) (21) Appl. No.: 13/544,789 (52) U.S. C. ......... 424/405; 514/784: 514/785: 514/396; (22) Filed: Jul. 9, 2012 514/399; 514/274: 514/231.2: 514/3.6; 514/31; 977/700; 977/906 Related U.S. Application Data (63) Continuation of application No. 12/430,700, filed on (57) ABSTRACT Apr. 27, 2009, now Pat. No. 8,226,965. The present invention relates to methods for treating and (60) Provisional application No. 61/048.075, filed on Apr. completely curing fungal, yeast, and/or mold infections in 25, 2008, provisional application No. 61/129,962, human Subjects comprising topically administering to a filed on Aug. 1, 2008, provisional application No. human Subject in need thereof an antifungal nanoemulsion 61/115,879, filed on Nov. 18, 2008. composition. Patent Application Publication Nov. 1, 2012 Sheet 1 of 26 US 2012/0276182 A1 go as g 9.
    [Show full text]